Targeted BRAF inhibitors (BRAFi) such as vemurafenib and dabrafenib are vital therapeutic options for melanoma patients carrying BRAF V600E mutation and demonstrate significant therapeutic efficacy [14, 15]. This evidence concerns the gene BRAF and melanoma.